|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing
epidemiology of small-cell lung cancer in the United States over
the last 30 years: Analysis of the surveillance, epidemiologic, and
end results database. J Clin Oncol. 24:4539–4544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bayman NA, Sheikh H, Kularatne B, Lorigan
P, Blackhall F, Thatcher N and Faivre-Finn C: Radiotherapy for
small-cell lung cancer-Where are we heading? Lung Cancer.
63:307–314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Turrisi AT III, Kim K, Blum R, Sause WT,
Livingston RB, Komaki R, Wagner H, Aisner S and Johnson DH:
Twice-daily compared with once-daily thoracic radiotherapy in
limited small-cell lung cancer treated concurrently with cisplatin
and etoposide. N Engl J Med. 340:265–271. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeremic B, Shibamoto Y, Nikolic N, Milicic
B, Milisavljevic S, Dagovic A, Aleksandrovic J and
Radosavljevic-Asic G: Role of radiation therapy in the
combined-modality treatment of patients with extensive disease
small-cell lung cancer: A randomized study. J Clin Oncol.
17:2092–2099. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Veronesi G, Bottoni E, Finocchiaro G and
Alloisio M: When is surgery indicated for small-cell lung cancer?
Lung Cancer. 90:582–589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Socha J and Kępka L: Prophylactic cranial
irradiation for small-cell lung cancer: How, when and for whom?
Expert Rev Anticancer Ther. 12:505–517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seute T, Leffers P, ten Velde GP and
Twijnstra A: Neurologic disorders in 432 consecutive patients with
small cell lung carcinoma. Cancer. 100:801–806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Komaki R, Cox JD and Whitson W: Risk of
brain metastasis from small cell carcinoma of the lung related to
length of survival and prophylactic irradiation. Cancer Treat Rep.
65:811–814. 1981.PubMed/NCBI
|
|
10
|
Zhu H, Guo H, Shi F, Zhu K, Luo J, Liu X,
Kong L and Yu J: Prophylactic cranial irradiation improved the
overall survival of patients with surgically resected small cell
lung cancer, but not for stage I disease. Lung Cancer. 86:334–338.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sunshine JC, Nguyen PL, Kaunitz GJ,
Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB,
Cornish TC, et al: PD-L1 expression in melanoma: A quantitative
immunohistochemical antibody comparison. Clin Cancer Res.
23:4938–4944. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He Y, Rozeboom L, Rivard CJ, Ellison K,
Dziadziuszko R, Yu H, Zhou C and Hirsch FR: PD-1, PD-L1 protein
expression in non-small cell lung cancer and their relationship
with tumor-infiltrating lymphocytes. Med Sci Monit. 23:1208–1216.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu H, Batenchuk C, Badzio A, Boyle TA,
Czapiewski P, Chan DC, Lu X, Gao D, Ellison K, Kowalewski AA, et
al: PD-L1 expression by two complementary diagnostic assays and
mRNA in situ hybridization in small cell lung cancer. J Thorac
Oncol. 12:110–120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Toyokawa G, Takada K, Haratake N, Takamori
S, Akamine T, Katsura M, Fujishita T, Shoji F, Okamoto T, Oda Y and
Maehara Y: Favorable disease-free survival associated with
programmed death ligand 1 expression in patients with surgically
resected small-cell lung cancer. Anticancer Res. 36:4329–4336.
2016.PubMed/NCBI
|
|
17
|
Ishii H, Azuma K, Kawahara A, Yamada K,
Imamura Y, Tokito T, Kinoshita T, Kage M and Hoshino T:
Significance of programmed cell death-ligand 1 expression and its
association with survival in patients with small cell lung cancer.
J Thorac Oncol. 10:426–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamane H, Isozaki H, Takeyama M, Ochi N,
Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K and Takigawa N:
Programmed cell death protein 1 and programmed death-ligand 1 are
expressed on the surface of some small-cell lung cancer lines. Am J
Cancer Res. 5:1553–1557. 2015.PubMed/NCBI
|
|
19
|
Schultheis AM, Scheel AH, Ozretić L,
George J, Thomas RK, Hagemann T, Zander T, Wolf J and Buettner R:
PD-L1 expression in small cell neuroendocrine carcinomas. Eur J
Cancer. 51:421–426. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong
L and Fan Y: PD-L1 and c-MET expression and survival in patients
with small cell lung cancer. Oncotarget. 8:53978–53988.
2017.PubMed/NCBI
|
|
21
|
Berghoff AS, Ricken G, Wilhelm D, Rajky O,
Widhalm G, Dieckmann K, Birner P, Bartsch R and Preusser M: Tumor
infiltrating lymphocytes and PD-L1 expression in brain metastases
of small cell lung cancer (SCLC). J Neurooncol. 130:19–29. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan F, Pang J, Peng Y, Molina JR, Yang P
and Liu S: Elevated cellular PD1/PD-L1 expression confers acquired
resistance to cisplatin in small cell lung cancer cells. PLoS One.
11:e01629252016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
George J, Saito M, Tsuta K, Iwakawa R,
Shiraishi K, Scheel AH, Uchida S, Watanabe SI, Nishikawa R, Noguchi
M, et al: Genomic amplification of CD274 (PD-L1) in small-cell lung
cancer. Clin Cancer Res. 23:1220–1226. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harter PN, Bernatz S, Scholz A, Zeiner PS,
Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, et
al: Distribution and prognostic relevance of tumor-infiltrating
lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain
metastases. Oncotarget. 6:40836–40849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kligerman S and Abbott G: A radiologic
review of the new TNM classification for lung cancer. AJR Am J
Roentgenol. 194:562–573. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liang SC, Latchman YE, Buhlmann JE,
Tomczak MF, Horwitz BH, Freeman GJ and Sharpe AH: Regulation of
PD-1, PD-L1 and PD-L2 expression during normal and autoimmune
responses. Eur J Immunol. 33:2706–2716. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lau J, Cheung J, Navarro A, Lianoglou S,
Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, et
al: Tumour and host cell PD-L1 is required to mediate suppression
of anti-tumour immunity in mice. Nat Commun. 8:145722017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Juneja VR, McGuire KA, Manguso RT, LaFleur
MW, Collins N, Haining WN, Freeman GJ and Sharpe AH: PD-L1 on tumor
cells is sufficient for immune evasion in immunogenic tumors and
inhibits CD8 T cell cytotoxicity. J Exp Med. 214:895–904. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Takada K, Toyokawa G, Okamoto T, Akamine
T, Takamori S, Katsura M, Fujishita T, Shoji F, Oda Y and Maehara
Y: An immunohistochemical analysis of PD-L1 protein expression in
surgically resected small cell lung cancer using different
antibodies and criteria. Anticancer Res. 36:3409–3412.
2016.PubMed/NCBI
|
